The extracellular vesicles targeting tumor microenvironment: a promising therapeutic strategy for melanoma.
cancer
extracellular vesicles
immunotherapy
melanoma
tumor microenvironment
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
04
2023
accepted:
18
07
2023
medline:
16
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Extracellular vesicles (EVs) are small particles secreted by numerous cell types and circulate in almost all body fluids, acting as crucial messengers for cell-to-cell communication. EVs involves multiple physiological and pathological processes, including tumor progression, via their multiple cargoes. Therefore, EVs have become attractive candidates for the treatment of tumor, including melanoma. Notably, due to the crucial role of the tumor microenvironment (TME) in promoting tumor malignant phenotype, and the close intercellular communication in TME, EVs-based therapy by targeting TME has become a cutting-edge and prospective strategy for inhibiting melanoma progression and strengthening the anti-tumor immunity. In this review, we aimed to summarize and discuss the role of therapeutic EVs, which target the components of TME in melanoma, thereby providing insights into these promising clinical strategies for the treatment of melanoma patients.
Identifiants
pubmed: 37575250
doi: 10.3389/fimmu.2023.1200249
pmc: PMC10419216
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1200249Informations de copyright
Copyright © 2023 Li and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Cell Mol Life Sci. 2021 Mar;78(6):3057-3072
pubmed: 33237352
Cancer Sci. 2021 Sep;112(9):3437-3454
pubmed: 34152672
Eur J Med Res. 2022 Oct 8;27(1):198
pubmed: 36209263
Mol Cancer. 2022 Jan 18;21(1):20
pubmed: 35042524
Cancers (Basel). 2020 Oct 06;12(10):
pubmed: 33036192
Eur J Cancer. 2022 Jul;170:236-255
pubmed: 35570085
Int J Cancer. 2017 Sep 15;141(6):1190-1200
pubmed: 28577299
Theranostics. 2017 Jul 7;7(10):2732-2745
pubmed: 28819459
Gut. 2022 Feb;71(2):333-344
pubmed: 33692094
Biomaterials. 2021 Nov;278:121137
pubmed: 34560422
Mol Cancer Ther. 2015 Apr;14(4):1035-47
pubmed: 25646015
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
J Immunother Cancer. 2019 Nov 27;7(1):326
pubmed: 31775862
Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67
pubmed: 21080821
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
pubmed: 31886121
Front Biosci (Landmark Ed). 2022 Sep 29;27(9):275
pubmed: 36224027
Front Immunol. 2020 Jul 30;11:1680
pubmed: 32849585
Anticancer Res. 2023 Jan;43(1):25-33
pubmed: 36585155
Int J Mol Sci. 2021 Dec 23;23(1):
pubmed: 35008569
J Transl Med. 2020 Feb 5;18(1):56
pubmed: 32024530
Nat Immunol. 2022 Aug;23(8):1148-1156
pubmed: 35879449
J Immunol Res. 2020 Jun 28;2020:9235638
pubmed: 32671117
J Am Heart Assoc. 2018 Feb 25;7(5):
pubmed: 29478968
Eurasian J Med. 2019 Feb;51(1):90-94
pubmed: 30911265
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Blood Adv. 2022 Mar 22;6(6):1879-1894
pubmed: 35130345
Ther Adv Med Oncol. 2020 Jul 16;12:1758835920937612
pubmed: 32728392
Cancer Gene Ther. 2022 Aug;29(8-9):1228-1239
pubmed: 35115683
Clin Cancer Res. 2008 Sep 15;14(18):5825-32
pubmed: 18794093
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
FEBS J. 2018 Mar;285(6):1033-1050
pubmed: 29399967
Cancer Res. 2019 Sep 15;79(18):4715-4728
pubmed: 31337655
Biochem Biophys Rep. 2021 Jul 27;27:101072
pubmed: 34381878
Acta Biomater. 2018 Aug;76:146-153
pubmed: 30078422
J Extracell Vesicles. 2015 Apr 20;4:26316
pubmed: 25899407
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Front Immunol. 2019 Oct 18;10:2459
pubmed: 31681332
Cancer Immunol Res. 2022 Aug 3;10(8):996-1012
pubmed: 35706413
Front Immunol. 2020 Dec 03;11:583084
pubmed: 33365025
Int J Mol Sci. 2019 Dec 20;21(1):
pubmed: 31861757
Cancer Sci. 2022 Apr;113(4):1168-1181
pubmed: 35043517
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
Front Immunol. 2020 Mar 13;11:262
pubmed: 32231660
Cell. 2019 Oct 31;179(4):829-845.e20
pubmed: 31675496
J Transl Med. 2020 Dec 10;18(1):474
pubmed: 33302971
Theranostics. 2018 Jun 24;8(14):3932-3948
pubmed: 30083271
FEBS J. 2022 Mar;289(5):1352-1368
pubmed: 33999497
Semin Cancer Biol. 2019 Dec;59:251-265
pubmed: 31386906
J Biol Chem. 2009 Dec 4;284(49):34211-22
pubmed: 19801663
J Surg Oncol. 2021 Mar;123(3):782-788
pubmed: 33002195
Cell Oncol (Dordr). 2021 Aug;44(4):715-737
pubmed: 33835425
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Extracell Vesicles. 2020 Oct;10(1):e12002
pubmed: 33304471
Semin Immunol. 2021 Feb;52:101481
pubmed: 34023170
Nanoscale. 2022 Jun 30;14(25):8995-9003
pubmed: 35700522
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Cancer Biol Ther. 2014 Jun 1;15(6):665-74
pubmed: 24651672
Biochem Soc Trans. 2019 Jun 28;47(3):811-826
pubmed: 31064864
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Angiogenesis. 2019 Aug;22(3):397-410
pubmed: 30993566
Curr Oncol Rep. 2019 Apr 26;21(6):54
pubmed: 31028497
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Cell Res. 2014 Oct;24(10):1164-80
pubmed: 25223704
J Clin Invest. 2020 Oct 1;130(10):5074-5087
pubmed: 32870818
Adv Mater. 2021 Aug;33(33):e2101110
pubmed: 34235790
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Oncol Rep. 2017 Aug;38(2):665-675
pubmed: 28627679
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
J Hematol Oncol. 2021 Sep 3;14(1):136
pubmed: 34479611
Nat Cell Biol. 2016 Sep;18(9):1006-17
pubmed: 27548915
J Immunol. 2012 Sep 15;189(6):2833-42
pubmed: 22904309
Int J Nanomedicine. 2020 Apr 21;15:2647-2658
pubmed: 32368046
Cell Oncol (Dordr). 2019 Feb;42(1):81-92
pubmed: 30276551
Front Immunol. 2021 Sep 10;12:734188
pubmed: 34567000
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
J Clin Oncol. 2022 Jan 10;40(2):127-137
pubmed: 34818112
Expert Rev Clin Pharmacol. 2019 May;12(5):453-470
pubmed: 30907177
J Exp Clin Cancer Res. 2018 Oct 3;37(1):242
pubmed: 30285793
Int J Mol Sci. 2021 Mar 26;22(7):
pubmed: 33810259
J Immunol Res. 2019 Feb 13;2019:3046379
pubmed: 30944831
Biomaterials. 2022 Oct;289:121765
pubmed: 36067566
Theranostics. 2021 Mar 11;11(11):5365-5386
pubmed: 33859752
Signal Transduct Target Ther. 2021 Feb 23;6(1):75
pubmed: 33619259
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
J Transl Med. 2022 Jul 16;20(1):320
pubmed: 35842634
Front Immunol. 2020 Jan 21;10:3038
pubmed: 32038612
Front Oncol. 2021 Feb 04;10:626129
pubmed: 33614507
Int J Mol Sci. 2023 Feb 12;24(4):
pubmed: 36835115
Int Immunopharmacol. 2022 Dec;113(Pt A):109320
pubmed: 36274482
Cancer Immunol Res. 2023 Feb 3;11(2):217-227
pubmed: 36546872
Blood. 2010 Mar 18;115(11):2167-76
pubmed: 19965656
J Hematol Oncol. 2020 Nov 19;13(1):156
pubmed: 33213490
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Int J Mol Sci. 2020 Jul 09;21(14):
pubmed: 32659938
Mol Genet Genomic Med. 2019 Sep;7(9):e870
pubmed: 31328440
Cancers (Basel). 2020 Nov 28;12(12):
pubmed: 33260606
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33526609
Nat Commun. 2020 Dec 8;11(1):6268
pubmed: 33293583
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Nat Metab. 2022 Dec;4(12):1660-1673
pubmed: 36376563
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
Theranostics. 2021 Feb 6;11(8):3932-3947
pubmed: 33664871
Cancer Res. 2022 Feb 1;82(3):419-432
pubmed: 35064015
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
J Clin Invest. 2022 Jun 1;132(11):
pubmed: 35642641
J Invest Dermatol. 2009 Jul;129(7):1614-27
pubmed: 19177135
Nat Commun. 2019 Sep 25;10(1):4355
pubmed: 31554797
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Cancer Cell. 2020 Dec 14;38(6):818-828.e5
pubmed: 33096021
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188456
pubmed: 33153973
Trends Mol Med. 2019 May;25(5):382-394
pubmed: 30853173
J Invest Dermatol. 2007 Jan;127(1):163-9
pubmed: 16858420
Cancer Immunol Res. 2019 Oct;7(10):1672-1686
pubmed: 31451482
Cell. 2015 Sep 10;162(6):1242-56
pubmed: 26359984
Pathol Oncol Res. 2019 Oct;25(4):1295-1301
pubmed: 30761449
Int J Mol Sci. 2022 Mar 21;23(6):
pubmed: 35328809
J Cell Biochem. 2008 Dec 1;105(5):1211-8
pubmed: 18802920
J Extracell Vesicles. 2019 Aug 1;8(1):1648167
pubmed: 31489144
Cancer Biomark. 2022;34(4):533-543
pubmed: 35275523
Int J Cancer. 2009 Jun 1;124(11):2621-33
pubmed: 19235923
Cell Prolif. 2017 Feb;50(1):
pubmed: 27667148
Acc Chem Res. 2020 Nov 17;53(11):2521-2533
pubmed: 33073988
Oncoimmunology. 2022 Apr 23;11(1):2067944
pubmed: 35481283
Eur J Immunol. 2020 Nov;50(11):1653-1662
pubmed: 32976623
Cancers (Basel). 2022 Oct 18;14(20):
pubmed: 36291876
Nat Cancer. 2021 Dec;2(12):1387-1405
pubmed: 34957415
J Cell Sci. 2019 Oct 15;132(20):
pubmed: 31615844
Semin Cancer Biol. 2020 May;62:192-200
pubmed: 31518697
Front Pharmacol. 2022 Apr 05;13:870347
pubmed: 35450036
Cell Cycle. 2019 Nov;18(22):3085-3094
pubmed: 31544590
Nat Immunol. 2021 May;22(5):560-570
pubmed: 33753940